Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limertinib plus Bevacizumab in EGFR-mutated NSCLC (LIBRA)
NCT06982924Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of limertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Progression-Free Survival at 2 years. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
limertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06982924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982924.